Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 12, 2026
Myriad Genetics Inc (MYGN)
A forensic read on Myriad Genetics Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-6.1
Distress distance
Clean
Earnings quality
6
Forensic signals
-2.7
P / E (ttm)
-99.4%
ROE
$308M
Market cap
0.00%
Dividend yield
-1.6%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Myriad Genetics Inc earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -6.1, placing it in the Distress zone. 6 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-63.4%
FY2025
Return on invested capital.Return on invested capital is -63.4% in the latest fiscal year and slipping from -11% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+4.7%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +15% over the last 3 years to FY2025 (+4.7%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~4.7% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~13%.
stopped
FY2019→FY2021
Shareholder returns — halted.Capital returns have STOPPED — $50M of buybacks + dividends in FY2019, but ~$0 in FY2021. A halt usually means the company is conserving cash.
43d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 36 to 43 FY2024→FY2025 (against cost of goods sold; inventory +11% vs -2% in cost of sales). Inventory is building a little faster than sales — watch for markdowns.
4% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 4% of revenue in FY2025 — about $0.38 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 4.8% a year and is falling.
Key fundamentals
Latest Revenue$824.5M
Revenue Growth YoY-1.6%
Revenue CAGR (3yr)+6.7%
Net Margin-44.4%
Free Cash Flow-$13.8M
Return on Equity-99.4%
Debt / Equity0.49x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Myriad Genetics Inc's actual 10-K/10-Q/8-K filings?
Goodwill impairments.Took $318M of goodwill writedowns across 3 years (FY2020 ($82M), FY2024 ($800,000), FY2025 ($235M)). Writedowns mean past acquisitions underperformed what was paid for them.